Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Гипертермия как дополнительная опция в лечении больных плоскоклеточным раком анального канала
Гипертермия как дополнительная опция в лечении больных плоскоклеточным раком анального канала
Глебовская В.В., Ткачев С.И., Иванов С.М. и др. Гипертермия как дополнительная опция в лечении больных плоскоклеточным раком анального канала. Современная Онкология. 2017; 19 (2): 48–52.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель: оценка уровня локорегионарного рецидивирования и отдаленного метастазирования, степени токсичности химиолучевой терапии при ее сочетании с локальной гипертермией (ГТ) у больных плоскоклеточным раком анального канала в стадии T1-4N0, 1-3M0-1.
Материалы и методы. С 2011 по 2015 г. 112 больным плоскоклеточным раком анального канала проведено комплексное лечение, включающее химиотерапию, 3D-конформную лучевую терапию и ее варианты – с модулированной интенсивностью (IMRT), объемно-модулированную лучевую терапию арками (VMAT) и локальную ГТ. Стадирование опухолевого процесса выполнялось по системе TNM (7-я редакция). I стадия установлена у 4 (3,6%) больных, II – у 39 (34,8%) больных; IIIA – у 33 (29,5%) больных, IIIB – у 34 (30,3%) больных и IV – у 2 (1,8%) больных. Медиана средней продолжительности прослеживания составила 32 мес (диапазон 3–63 мес). Локальная ГТ проведена 81 (72,3%) пациенту.
Результаты. В течение 2-летнего периода наблюдения опухоль не определяется у 82 (73,2%) больных. Все рецидивы, вне зависимости от варианта комплексного лечения, возникли при местно-распространенной форме (IIIA/IIIB стадии болезни), из них достоверно чаще 22,2% в группе без применения ГТ и 4,7% – в группе с применением радиомодификатора, p=0,038. Отдаленные метастазы выявлены в 9,4% случаев у пациентов, получивших ГТ, и в 11,1% случаев при отсутствии радиомодификатора, p=1. Установлено также, что применение локальной ГТ ассоциируется с достоверным увеличением ранней дерматологической токсичности 2-й степени, p=0,056.
Выводы. Локальная ГТ и усовершенствованные технологии конформной лучевой терапии повлияли достоверно на уменьшение частоты локорегионарных рецидивов. Однако их влияние на уменьшение отдаленного метастазирования отсутствует вне зависимости от комбинации в схемах химиотерапии. Переносимость сочетанного использования химиолучевой терапии с ГТ не вызвала дополнительных осложнений.
Ключевые слова: локальная электромагнитная гипертермия, плоскоклеточный рак анального канала, лучевая терапия с модулированной интенсивностью.
Materials and methods. 112 patients with squamous cell anal canal cancer were treated between 2011 and 2015 with chemotherapy, radiation therapy based on 3D CRT, intensity-modulated radiation therapy (IMRT) and volumetric intensity modulated arc therapy (VMAT), and local hypothermia. Staging was based on TNM (7th edition): I – 4 (3.6%) patients, II – 39 (34.8%) patients; IIIA – 33 (29.5%) patients, IIIB – 34 (30.3%) patients and IV – 2 (1.8%) patients. The median of mean follow-up was 32 months (range, 3–63 months). Local hyperthermia was performed in 81 (72.3%) patients.
Results. 2-year local control was 73.2%. All recurrences, no matter which chemotherapy was performed, were in patients with advanced disease (IIIA/IIIB stages), from which 22.2% relapses were in group without local hyperthermia vs. 4.7% in group with radiomodification, p=0.038. Distant metastases were found in 9.4% patients with hyperthermia and in 11.1% patients without radiomodification, p=1. Usage of local hyperthermia is associated with increase II grade of dermatological toxicity (p=0.056).
Conclusion. The combination of local hyperthermia and modern technologies of conformal radiation therapy has influenced the decrease of locoregional recurrences, but it is associated with lack of influence on distant metastases appearance regardless on chemotherapy regimen.
Key words: local hyperthermia, squamous cell carcinoma of the anal canal, intensity modulated radiation therapy.
Материалы и методы. С 2011 по 2015 г. 112 больным плоскоклеточным раком анального канала проведено комплексное лечение, включающее химиотерапию, 3D-конформную лучевую терапию и ее варианты – с модулированной интенсивностью (IMRT), объемно-модулированную лучевую терапию арками (VMAT) и локальную ГТ. Стадирование опухолевого процесса выполнялось по системе TNM (7-я редакция). I стадия установлена у 4 (3,6%) больных, II – у 39 (34,8%) больных; IIIA – у 33 (29,5%) больных, IIIB – у 34 (30,3%) больных и IV – у 2 (1,8%) больных. Медиана средней продолжительности прослеживания составила 32 мес (диапазон 3–63 мес). Локальная ГТ проведена 81 (72,3%) пациенту.
Результаты. В течение 2-летнего периода наблюдения опухоль не определяется у 82 (73,2%) больных. Все рецидивы, вне зависимости от варианта комплексного лечения, возникли при местно-распространенной форме (IIIA/IIIB стадии болезни), из них достоверно чаще 22,2% в группе без применения ГТ и 4,7% – в группе с применением радиомодификатора, p=0,038. Отдаленные метастазы выявлены в 9,4% случаев у пациентов, получивших ГТ, и в 11,1% случаев при отсутствии радиомодификатора, p=1. Установлено также, что применение локальной ГТ ассоциируется с достоверным увеличением ранней дерматологической токсичности 2-й степени, p=0,056.
Выводы. Локальная ГТ и усовершенствованные технологии конформной лучевой терапии повлияли достоверно на уменьшение частоты локорегионарных рецидивов. Однако их влияние на уменьшение отдаленного метастазирования отсутствует вне зависимости от комбинации в схемах химиотерапии. Переносимость сочетанного использования химиолучевой терапии с ГТ не вызвала дополнительных осложнений.
Ключевые слова: локальная электромагнитная гипертермия, плоскоклеточный рак анального канала, лучевая терапия с модулированной интенсивностью.
________________________________________________
Materials and methods. 112 patients with squamous cell anal canal cancer were treated between 2011 and 2015 with chemotherapy, radiation therapy based on 3D CRT, intensity-modulated radiation therapy (IMRT) and volumetric intensity modulated arc therapy (VMAT), and local hypothermia. Staging was based on TNM (7th edition): I – 4 (3.6%) patients, II – 39 (34.8%) patients; IIIA – 33 (29.5%) patients, IIIB – 34 (30.3%) patients and IV – 2 (1.8%) patients. The median of mean follow-up was 32 months (range, 3–63 months). Local hyperthermia was performed in 81 (72.3%) patients.
Results. 2-year local control was 73.2%. All recurrences, no matter which chemotherapy was performed, were in patients with advanced disease (IIIA/IIIB stages), from which 22.2% relapses were in group without local hyperthermia vs. 4.7% in group with radiomodification, p=0.038. Distant metastases were found in 9.4% patients with hyperthermia and in 11.1% patients without radiomodification, p=1. Usage of local hyperthermia is associated with increase II grade of dermatological toxicity (p=0.056).
Conclusion. The combination of local hyperthermia and modern technologies of conformal radiation therapy has influenced the decrease of locoregional recurrences, but it is associated with lack of influence on distant metastases appearance regardless on chemotherapy regimen.
Key words: local hyperthermia, squamous cell carcinoma of the anal canal, intensity modulated radiation therapy.
Полный текст
Список литературы
1. Van der Zee J, González González D, van Rhoon GC et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–25.
2. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol 2014; 41: 714–29.
3. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19: 418–26.
4. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994; 10: 457–83.
5. Ткачев С.И. Сочетанное применение лучевой терапии и локальной гипертермии в лечении местнораспространенных новообразований. Дис. … д-ра мед. наук, 1994. / Tkachev S.I. Sochetannoe primenenie luchevoi terapii i lokal'noi gipertermii v lechenii mestnorasprostranennykh novoobrazovanii. Dis. … d-ra med. nauk, 1994. [in Russian]
6. Кныш В.И., Тимофеев Ю.М. Злокачественные опухоли анального канала. М., 1997. / Knysh V.I., Timofeev Iu.M., Zlokachestvennye opukholi anal'nogo kanala. M., 1997. [in Russian]
7. Малихов А.Г. Комбинированное и комплексное лечение больных плоскоклеточным раком анального канала. Дис. … канд. мед. наук. М., 2003. / Malikhov A.G. Kombinirovannoe i kompleksnoe lechenie bol'nykh ploskokletochnym rakom anal'nogo kanala. Dis. … kand. med. nauk. M., 2003. [in Russian]
8. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009; 10 (6): 550–8.
9. Bull JMC, Strebel FR, Jenkins GN et al. The importance of schedule in whole body thermochemotherapy. Int J Hyperthermia 2008; 24 (2): 171–81.
10. Liang XH, He YW, Tang YL et al. Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg 2009.
11. Atmaca A, Al-Batran SE, Neumann A et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer: a phase II study. Gynecol Oncol 2009; 112 (2): 384–8.
12. Thrall DE, LaRue SM, Yu D et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res 2005; 11 (14): 5206–14.
13. Arora D, Skliar M, Roemer RB. Minimum-time thermal dose control of thermal therapies. IEEE Trans Biomed Eng 2005; 52 (2): 191–200.
14. Jones EL, Pronisnitz LR, Dewhirst MW et al. In regard to Vasanathan et al. Int J Radiat Oncol Biol Phys 2005; 63: 644.
15. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int J Radiat Oncol Biol Phys 1996; 35: 731–44.
16. Franckena M, Canters R, Termorshuizen F et al. Clinical implementation of hyperthermia treatment planning guided steering: a cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010; 26: 145–57.
17. Franckena M, Stalpers LJ, Koper PC et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys 2008; 70: 1176–82.
18. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6: 881–90.
19. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009; CD006269.
20. Rau B, Benhidjeb T, Wust P, Schlag PM. Stellenwert der Hyperthermie fur die chirurgische Onkologie. German Viszeralchirurgie 2002; 37: 379–84.
21. Issels RD, Lindner LH, Verweij J et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561–70.
22. Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20.
23. Kouloulias V, Plataniotis G, Kouvaris J et al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005; 28: 91–9.
24. Colombo R, Salonia A, Leib Z et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (nmibc). BJU Int 2011; 107: 912–8.
25. Ott OJ, Rodel C, Weiss C et al. Radiochemotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol) 2009; 21: 557–65.
26. Wittlinger M, Rodel CM, Weiss C et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009; 93: 358–63.
27. Gellermann J, Wlodarczyk W, Hildebrandt B et al. Noninvasive magnetic resonance thermography of recurrent rectal caecinoma in a 1.5 Tesla hybrid system. Cancer Res 2005; 65: 5872–80.
28. Gellermann J, Hildebrandt B, Issels R et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006; 107: 1373–82.
29. Datta NR, Puric E, Schneider R et al. Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. Int J Hyperthermia 2014; 30: 524–30.
30. Issels R. Hyperthermia combined with chemotherapy – biological rationale, clinical application, and treatment results. Onkologie 1999; 22: 374–81.
31. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–90.
32. Sneed PK, Stauffer PR, McDermott MW et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287–95.
33. Zhao C, Chen J, Yu B, Chen X. Improvement in quality of life in patients with nasopharyngeal carcinoma treated with non-invasive extracorporeal radiofrequency in combination with chemoradiotherapy. Int J Radiat Biol 2014; 90: 853–8.
34. Cox JD et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341–6.
35. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 1994; 10: 485–93.
36. Schaffer M, Krych M, Pachmann S et al. Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer – preliminary results. Onkologie 2003; 26: 120–4.
37. Голдобенко Г.В., Дурнов Л.А., Кныш В.И. и др. Опыт терморадиотерапии злокачественных опухолей. Мед. радиология. 1987; 1: 36–8. / Goldobenko G.V., Durnov L.A., Knysh V.I. i dr. Opyt termoradioterapii zlokachestvennykh opukholei. Med. radiologiia. 1987; 1: 36–8. [in Russian]
2. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol 2014; 41: 714–29.
3. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19: 418–26.
4. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994; 10: 457–83.
5. Tkachev S.I. Sochetannoe primenenie luchevoi terapii i lokal'noi gipertermii v lechenii mestnorasprostranennykh novoobrazovanii. Dis. … d-ra med. nauk, 1994. [in Russian]
6. Knysh V.I., Timofeev Iu.M., Zlokachestvennye opukholi anal'nogo kanala. M., 1997. [in Russian]
7. Malikhov A.G. Kombinirovannoe i kompleksnoe lechenie bol'nykh ploskokletochnym rakom anal'nogo kanala. Dis. … kand. med. nauk. M., 2003. [in Russian]
8. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009; 10 (6): 550–8.
9. Bull JMC, Strebel FR, Jenkins GN et al. The importance of schedule in whole body thermochemotherapy. Int J Hyperthermia 2008; 24 (2): 171–81.
10. Liang XH, He YW, Tang YL et al. Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg 2009.
11. Atmaca A, Al-Batran SE, Neumann A et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer: a phase II study. Gynecol Oncol 2009; 112 (2): 384–8.
12. Thrall DE, LaRue SM, Yu D et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res 2005; 11 (14): 5206–14.
13. Arora D, Skliar M, Roemer RB. Minimum-time thermal dose control of thermal therapies. IEEE Trans Biomed Eng 2005; 52 (2): 191–200.
14. Jones EL, Pronisnitz LR, Dewhirst MW et al. In regard to Vasanathan et al. Int J Radiat Oncol Biol Phys 2005; 63: 644.
15. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int J Radiat Oncol Biol Phys 1996; 35: 731–44.
16. Franckena M, Canters R, Termorshuizen F et al. Clinical implementation of hyperthermia treatment planning guided steering: a cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010; 26: 145–57.
17. Franckena M, Stalpers LJ, Koper PC et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys 2008; 70: 1176–82.
18. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6: 881–90.
19. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009; CD006269.
20. Rau B, Benhidjeb T, Wust P, Schlag PM. Stellenwert der Hyperthermie fur die chirurgische Onkologie. German Viszeralchirurgie 2002; 37: 379–84.
21. Issels RD, Lindner LH, Verweij J et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561–70.
22. Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20.
23. Kouloulias V, Plataniotis G, Kouvaris J et al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005; 28: 91–9.
24. Colombo R, Salonia A, Leib Z et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (nmibc). BJU Int 2011; 107: 912–8.
25. Ott OJ, Rodel C, Weiss C et al. Radiochemotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol) 2009; 21: 557–65.
26. Wittlinger M, Rodel CM, Weiss C et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009; 93: 358–63.
27. Gellermann J, Wlodarczyk W, Hildebrandt B et al. Noninvasive magnetic resonance thermography of recurrent rectal caecinoma in a 1.5 Tesla hybrid system. Cancer Res 2005; 65: 5872–80.
28. Gellermann J, Hildebrandt B, Issels R et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006; 107: 1373–82.
29. Datta NR, Puric E, Schneider R et al. Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. Int J Hyperthermia 2014; 30: 524–30.
30. Issels R. Hyperthermia combined with chemotherapy – biological rationale, clinical application, and treatment results. Onkologie 1999; 22: 374–81.
31. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–90.
32. Sneed PK, Stauffer PR, McDermott MW et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287–95.
33. Zhao C, Chen J, Yu B, Chen X. Improvement in quality of life in patients with nasopharyngeal carcinoma treated with non-invasive extracorporeal radiofrequency in combination with chemoradiotherapy. Int J Radiat Biol 2014; 90: 853–8.
34. Cox JD et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341–6.
35. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 1994; 10: 485–93.
36. Schaffer M, Krych M, Pachmann S et al. Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer – preliminary results. Onkologie 2003; 26: 120–4.
37. Goldobenko G.V., Durnov L.A., Knysh V.I. i dr. Opyt termoradioterapii zlokachestvennykh opukholei. Med. radiologiia. 1987; 1: 36–8. [in Russian]
2. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol 2014; 41: 714–29.
3. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19: 418–26.
4. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994; 10: 457–83.
5. Ткачев С.И. Сочетанное применение лучевой терапии и локальной гипертермии в лечении местнораспространенных новообразований. Дис. … д-ра мед. наук, 1994. / Tkachev S.I. Sochetannoe primenenie luchevoi terapii i lokal'noi gipertermii v lechenii mestnorasprostranennykh novoobrazovanii. Dis. … d-ra med. nauk, 1994. [in Russian]
6. Кныш В.И., Тимофеев Ю.М. Злокачественные опухоли анального канала. М., 1997. / Knysh V.I., Timofeev Iu.M., Zlokachestvennye opukholi anal'nogo kanala. M., 1997. [in Russian]
7. Малихов А.Г. Комбинированное и комплексное лечение больных плоскоклеточным раком анального канала. Дис. … канд. мед. наук. М., 2003. / Malikhov A.G. Kombinirovannoe i kompleksnoe lechenie bol'nykh ploskokletochnym rakom anal'nogo kanala. Dis. … kand. med. nauk. M., 2003. [in Russian]
8. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009; 10 (6): 550–8.
9. Bull JMC, Strebel FR, Jenkins GN et al. The importance of schedule in whole body thermochemotherapy. Int J Hyperthermia 2008; 24 (2): 171–81.
10. Liang XH, He YW, Tang YL et al. Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg 2009.
11. Atmaca A, Al-Batran SE, Neumann A et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer: a phase II study. Gynecol Oncol 2009; 112 (2): 384–8.
12. Thrall DE, LaRue SM, Yu D et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res 2005; 11 (14): 5206–14.
13. Arora D, Skliar M, Roemer RB. Minimum-time thermal dose control of thermal therapies. IEEE Trans Biomed Eng 2005; 52 (2): 191–200.
14. Jones EL, Pronisnitz LR, Dewhirst MW et al. In regard to Vasanathan et al. Int J Radiat Oncol Biol Phys 2005; 63: 644.
15. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int J Radiat Oncol Biol Phys 1996; 35: 731–44.
16. Franckena M, Canters R, Termorshuizen F et al. Clinical implementation of hyperthermia treatment planning guided steering: a cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010; 26: 145–57.
17. Franckena M, Stalpers LJ, Koper PC et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys 2008; 70: 1176–82.
18. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6: 881–90.
19. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009; CD006269.
20. Rau B, Benhidjeb T, Wust P, Schlag PM. Stellenwert der Hyperthermie fur die chirurgische Onkologie. German Viszeralchirurgie 2002; 37: 379–84.
21. Issels RD, Lindner LH, Verweij J et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561–70.
22. Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20.
23. Kouloulias V, Plataniotis G, Kouvaris J et al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005; 28: 91–9.
24. Colombo R, Salonia A, Leib Z et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (nmibc). BJU Int 2011; 107: 912–8.
25. Ott OJ, Rodel C, Weiss C et al. Radiochemotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol) 2009; 21: 557–65.
26. Wittlinger M, Rodel CM, Weiss C et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009; 93: 358–63.
27. Gellermann J, Wlodarczyk W, Hildebrandt B et al. Noninvasive magnetic resonance thermography of recurrent rectal caecinoma in a 1.5 Tesla hybrid system. Cancer Res 2005; 65: 5872–80.
28. Gellermann J, Hildebrandt B, Issels R et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006; 107: 1373–82.
29. Datta NR, Puric E, Schneider R et al. Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. Int J Hyperthermia 2014; 30: 524–30.
30. Issels R. Hyperthermia combined with chemotherapy – biological rationale, clinical application, and treatment results. Onkologie 1999; 22: 374–81.
31. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–90.
32. Sneed PK, Stauffer PR, McDermott MW et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287–95.
33. Zhao C, Chen J, Yu B, Chen X. Improvement in quality of life in patients with nasopharyngeal carcinoma treated with non-invasive extracorporeal radiofrequency in combination with chemoradiotherapy. Int J Radiat Biol 2014; 90: 853–8.
34. Cox JD et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341–6.
35. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 1994; 10: 485–93.
36. Schaffer M, Krych M, Pachmann S et al. Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer – preliminary results. Onkologie 2003; 26: 120–4.
37. Голдобенко Г.В., Дурнов Л.А., Кныш В.И. и др. Опыт терморадиотерапии злокачественных опухолей. Мед. радиология. 1987; 1: 36–8. / Goldobenko G.V., Durnov L.A., Knysh V.I. i dr. Opyt termoradioterapii zlokachestvennykh opukholei. Med. radiologiia. 1987; 1: 36–8. [in Russian]
________________________________________________
2. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol 2014; 41: 714–29.
3. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19: 418–26.
4. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994; 10: 457–83.
5. Tkachev S.I. Sochetannoe primenenie luchevoi terapii i lokal'noi gipertermii v lechenii mestnorasprostranennykh novoobrazovanii. Dis. … d-ra med. nauk, 1994. [in Russian]
6. Knysh V.I., Timofeev Iu.M., Zlokachestvennye opukholi anal'nogo kanala. M., 1997. [in Russian]
7. Malikhov A.G. Kombinirovannoe i kompleksnoe lechenie bol'nykh ploskokletochnym rakom anal'nogo kanala. Dis. … kand. med. nauk. M., 2003. [in Russian]
8. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 2009; 10 (6): 550–8.
9. Bull JMC, Strebel FR, Jenkins GN et al. The importance of schedule in whole body thermochemotherapy. Int J Hyperthermia 2008; 24 (2): 171–81.
10. Liang XH, He YW, Tang YL et al. Thermochemotherapy of lower lip squamous cell carcinoma without metastases: an experience of 31 cases. J Craniomaxillofac Surg 2009.
11. Atmaca A, Al-Batran SE, Neumann A et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer: a phase II study. Gynecol Oncol 2009; 112 (2): 384–8.
12. Thrall DE, LaRue SM, Yu D et al. Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res 2005; 11 (14): 5206–14.
13. Arora D, Skliar M, Roemer RB. Minimum-time thermal dose control of thermal therapies. IEEE Trans Biomed Eng 2005; 52 (2): 191–200.
14. Jones EL, Pronisnitz LR, Dewhirst MW et al. In regard to Vasanathan et al. Int J Radiat Oncol Biol Phys 2005; 63: 644.
15. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int J Radiat Oncol Biol Phys 1996; 35: 731–44.
16. Franckena M, Canters R, Termorshuizen F et al. Clinical implementation of hyperthermia treatment planning guided steering: a cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010; 26: 145–57.
17. Franckena M, Stalpers LJ, Koper PC et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch deep hyperthermia trial. Int J Radiat Oncol Biol Phys 2008; 70: 1176–82.
18. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6: 881–90.
19. De Haas-Kock DF, Buijsen J, Pijls-Johannesma M et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev 2009; CD006269.
20. Rau B, Benhidjeb T, Wust P, Schlag PM. Stellenwert der Hyperthermie fur die chirurgische Onkologie. German Viszeralchirurgie 2002; 37: 379–84.
21. Issels RD, Lindner LH, Verweij J et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010; 11: 561–70.
22. Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20.
23. Kouloulias V, Plataniotis G, Kouvaris J et al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005; 28: 91–9.
24. Colombo R, Salonia A, Leib Z et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for non-muscle-invasive bladder cancer (nmibc). BJU Int 2011; 107: 912–8.
25. Ott OJ, Rodel C, Weiss C et al. Radiochemotherapy for Bladder Cancer. Clin Oncol (R Coll Radiol) 2009; 21: 557–65.
26. Wittlinger M, Rodel CM, Weiss C et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009; 93: 358–63.
27. Gellermann J, Wlodarczyk W, Hildebrandt B et al. Noninvasive magnetic resonance thermography of recurrent rectal caecinoma in a 1.5 Tesla hybrid system. Cancer Res 2005; 65: 5872–80.
28. Gellermann J, Hildebrandt B, Issels R et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 2006; 107: 1373–82.
29. Datta NR, Puric E, Schneider R et al. Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. Int J Hyperthermia 2014; 30: 524–30.
30. Issels R. Hyperthermia combined with chemotherapy – biological rationale, clinical application, and treatment results. Onkologie 1999; 22: 374–81.
31. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21: 779–90.
32. Sneed PK, Stauffer PR, McDermott MW et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287–95.
33. Zhao C, Chen J, Yu B, Chen X. Improvement in quality of life in patients with nasopharyngeal carcinoma treated with non-invasive extracorporeal radiofrequency in combination with chemoradiotherapy. Int J Radiat Biol 2014; 90: 853–8.
34. Cox JD et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341–6.
35. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 1994; 10: 485–93.
36. Schaffer M, Krych M, Pachmann S et al. Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer – preliminary results. Onkologie 2003; 26: 120–4.
37. Goldobenko G.V., Durnov L.A., Knysh V.I. i dr. Opyt termoradioterapii zlokachestvennykh opukholei. Med. radiologiia. 1987; 1: 36–8. [in Russian]
Авторы
В.В.Глебовская*, С.И.Ткачев, С.М.Иванов, А.В.Назаренко, А.О.Расулов, С.С.Гордеев, П.В.Булычкин, Н.С.Бесова, Ю.А.Барсуков, О.П.Трофимова, Т.Н.Борисова, Е.В.Тимошкина
ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
*oncovalery@mail.ru
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*oncovalery@mail.ru
ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
*oncovalery@mail.ru
________________________________________________
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*oncovalery@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.